新生儿戒断综合征患儿头围偏小
前瞻性队列研究纳入858名新生儿(429例因新生儿戒断综合征接受治疗,429例无阿片暴露对照),匹配种族、产次、分娩方式和胎龄。结果显示病例组平均头围33.04 cm,对照组33.99 cm(P < .0001);病例组30.1%头围≤第10百分位,8.2%≤第3百分位。多因素分析显示仅孕期慢性阿片使用导致新生儿戒断综合征是头围偏小的显著危险因素。
要点
- 30.1%的患儿头围≤第10百分位,8.2%≤第3百分位。
- 孕期慢性阿片使用导致新生儿戒断综合征是头围偏小的显著危险因素。
核心结论
- 孕期慢性阿片使用足以导致新生儿戒断综合征时,与出生时头围偏小相关。
研究设计与样本
- 前瞻性队列研究,2014年4月1日至2016年12月31日,纳入胎龄≥34周、因新生儿戒断综合征治疗的新生儿与无阿片暴露对照,按种族、产次、分娩方式和胎龄匹配。
- 共纳入858名新生儿(429例病例和429例对照),所有母亲均接受系列产前尿液药物检测。
主要发现
- 病例组平均头围33.04 cm(±1.9 cm),对照组33.99 cm(±2.0 cm),P < .0001。
- 429例病例中,30.1%(95%CI:25.8%-34.7%)头围≤第10百分位(129/429),8.2%(95%CI:5.8%-11.2%)头围≤第3百分位(35/429)。
- 429例病例中372例(87%)母亲接受阿片类药物辅助治疗。
- 多因素分析确定仅孕期慢性阿片使用导致新生儿戒断综合征是头围偏小的显著危险因素。
关键数值与推荐
- 样本量估算:需至少754名参与者(每组377名)以90%把握度证明头围≤第10百分位比例从对照组10%增至病例组至少20%。
临床怎么用
- 对因新生儿戒断综合征治疗的新生儿应关注头围测量,警惕头围≤第10百分位或≤第3百分位。
- 多数母亲孕期接受阿片受体激动剂辅助治疗,该治疗为当前孕期推荐方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare head circumference (HC) in neonates treated for neonatal abstinence syndrome (NAS) with control neonates without antenatal opioid exposure. METHODS: Our prospective cohort study ran from April 1, 2014, through December 31, 2016. Newborns treated for NAS delivered from well-dated pregnancies ≥34 weeks' gestation were compared with newborns who were nonopioid exposed and matched for race, parity, mode of delivery, and gestational age. All mothers underwent serial antenatal urine drug testing. A minimum of 754 study participants were needed (377 in each group) to demonstrate an increase in the proportion of newborns with HCs less than or equal to the 10th percentile from 10% in controls to a minimum of 20% in NAS newborns with 90% power. RESULTS: A total of 858 neonates were enrolled (429 NAS cases and 429 controls). Mean HC for cases was 33.04 cm (±1.9 cm) compared with 33.99 cm (±2.0 cm) for controls (P < .0001). Among the 429 NAS cases, the mothers of 372 (87%) were on opioid medication-assisted treatment. For NAS cases, 30.1% (95% confidence interval: 25.8%-34.7%) had an HC less than or equal to the 10th percentile (129 of 429 neonates), and 8.2% (95% confidence interval: 5.8%-11.2%) had an HC less than or equal to the third percentile (35 of 429 neonates). Multivariate analysis was used and determined that only chronic opioid use during gestation resulting in a neonate who was NAS treated was a significant risk factor for the observed smaller HC. CONCLUSIONS: Chronic opioid use during pregnancy sufficient to cause NAS was associated with smaller HCs at birth. Most mothers were on opioid agonist medication-assisted treatment, which is currently the recommended treatment option during pregnancy.
引用
- Towers CV, Hyatt BW, Visconti KC, et al. Neonatal Head Circumference in Newborns With Neonatal Abstinence Syndrome. Pediatrics. 2018. PMID: 30530638. doi:10.1542/peds.2018-0541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。